Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Patricia A. Ropp is active.

Publication


Featured researches published by Patricia A. Ropp.


Proceedings of the National Academy of Sciences of the United States of America | 2008

The effect of particle design on cellular internalization pathways

Stephanie E. A. Gratton; Patricia A. Ropp; Patrick D. Pohlhaus; J. Christopher Luft; Victoria J. Madden; Mary E. Napier; Joseph M. DeSimone

The interaction of particles with cells is known to be strongly influenced by particle size, but little is known about the interdependent role that size, shape, and surface chemistry have on cellular internalization and intracellular trafficking. We report on the internalization of specially designed, monodisperse hydrogel particles into HeLa cells as a function of size, shape, and surface charge. We employ a top-down particle fabrication technique called PRINT that is able to generate uniform populations of organic micro- and nanoparticles with complete control of size, shape, and surface chemistry. Evidence of particle internalization was obtained by using conventional biological techniques and transmission electron microscopy. These findings suggest that HeLa cells readily internalize nonspherical particles with dimensions as large as 3 μm by using several different mechanisms of endocytosis. Moreover, it was found that rod-like particles enjoy an appreciable advantage when it comes to internalization rates, reminiscent of the advantage that many rod-like bacteria have for internalization in nonphagocytic cells.


Journal of the American Chemical Society | 2008

Reductively Labile PRINT Particles for the Delivery of Doxorubicin to HeLa Cells

Robby A. Petros; Patricia A. Ropp; Joseph M. DeSimone

A Trojan horse PRINT particle composition was developed that incorporates a reductively labile cross-linker to achieve activated release of doxorubicin in vitro. Particles of discrete size and shape (cube side length = 2 micron) containing 30 wt % of a disulfide-based cross-linker and 2 wt % doxorubicin were synthesized. This PRINT composition was shown to release doxorubicin in response to a reducing environment as measured by flow cytometry and was found to be highly proficient at killing HeLa cells in vitro.


Archives of Biochemistry and Biophysics | 1991

Allosteric regulation of purine nucleoside phosphorylase

Patricia A. Ropp; Thomas W. Traut

Purine nucleoside phosphorylase (EC 2.4.2.1) from bovine spleen is allosterically regulated. With the substrate inosine the enzyme displayed complex kinetics: positive cooperativity vs inosine when this substrate was close to physiological concentrations, negative cooperativity at inosine concentrations greater than 60 microM, and substrate inhibition at inosine greater than 1 mM. No cooperativity was observed with the alternative substrate, guanosine. The activity of purine nucleoside phosphorylase toward the substrate inosine was sensitive to the presence of reducing thiols; oxidation caused a loss of cooperativity toward inosine, as well as a 10-fold decreased affinity for inosine. The enzyme also displayed negative cooperativity toward phosphate at physiological concentrations of Pi, but oxidation had no effect on either the affinity or cooperativity toward phosphate. The importance of reduced cysteines on the enzyme is thus specific for binding of the nucleoside substrate. The enzyme was modestly inhibited by the pyrimidine nucleotides CTP (Ki = 118 microM) and UTP (Ki = 164 microM), but showed greater sensitivity to 5-phosphoribosyl-1-pyrophosphate (Ki = 5.2 microM).


Clinical Cancer Research | 2013

A Novel HLA-A*0201 Restricted Peptide Derived from Cathepsin G Is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia

Mao Zhang; Pariya Sukhumalchandra; Atim A. Enyenihi; Lisa S. St. John; Sally A. Hunsucker; Elizabeth A. Mittendorf; Anna Sergeeva; Kathryn Ruisaard; Zein Al-Atrache; Patricia A. Ropp; Haroon Jakher; Tania Rodriguez-Cruz; Gregory Lizée; Karen Clise-Dwyer; Sijie Lu; Jeffrey J. Molldrem; Gary L. Glish; Paul M. Armistead; Gheath Alatrash

Purpose: Immunotherapy targeting aberrantly expressed leukemia-associated antigens has shown promise in the management of acute myeloid leukemia (AML). However, because of the heterogeneity and clonal evolution that is a feature of myeloid leukemia, targeting single peptide epitopes has had limited success, highlighting the need for novel antigen discovery. In this study, we characterize the role of the myeloid azurophil granule protease cathepsin G (CG) as a novel target for AML immunotherapy. Experimental Design: We used Immune Epitope Database and in vitro binding assays to identify immunogenic epitopes derived from CG. Flow cytometry, immunoblotting, and confocal microscopy were used to characterize the expression and processing of CG in AML patient samples, leukemia stem cells, and normal neutrophils. Cytotoxicity assays determined the susceptibility of AML to CG-specific cytotoxic T lymphocytes (CTL). Dextramer staining and cytokine flow cytometry were conducted to characterize the immune response to CG in patients. Results: CG was highly expressed and ubiquitinated in AML blasts, and was localized outside granules in compartments that facilitate antigen presentation. We identified five HLA-A*0201 binding nonameric peptides (CG1-CG5) derived from CG, and showed immunogenicity of the highest HLA-A*0201 binding peptide, CG1. We showed killing of primary AML by CG1-CTL, but not normal bone marrow. Blocking HLA-A*0201 abrogated CG1-CTL–mediated cytotoxicity, further confirming HLA-A*0201-dependent killing. Finally, we showed functional CG1-CTLs in peripheral blood from AML patients following allogeneic stem cell transplantation. Conclusion: CG is aberrantly expressed and processed in AML and is a novel immunotherapeutic target that warrants further development. Clin Cancer Res; 19(1); 247–57. ©2012 AACR.


Cancer immunology research | 2015

Peptide/MHC tetramer-based sorting of CD8 T cells to a Leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire

Sally A. Hunsucker; Colleen S. McGary; Benjamin G. Vincent; Atim A. Enyenihi; Jennifer P. Waugh; Karen P. McKinnon; Lisa M. Bixby; Patricia A. Ropp; James Coghill; William A. Wood; Don A. Gabriel; Stefanie Sarantopoulos; Thomas C. Shea; Jonathan S. Serody; Gheath Alatrash; Tania Rodriguez-Cruz; Gregory Lizée; Adam Buntzman; Jeffrey A. Frelinger; Gary L. Glish; Paul M. Armistead

Hunsucker, McGary, Vincent, and colleagues report that low-frequency, antigen-specific T-cell responses may be specifically tested using tetramer-based, single-cell sorting and sequencing of the antigen-specific TCRβ clonotypes, and then mapping them onto a patients TCRβ to quantify antigen-driven clonal expansion. Testing of T cell–based cancer therapeutics often involves measuring cancer antigen–specific T-cell populations with the assumption that they arise from in vivo clonal expansion. This analysis, using peptide/MHC tetramers, is often ambiguous. From a leukemia cell line, we identified a CDK4-derived peptide epitope, UNC-CDK4-1 (ALTPVVVTL), that bound HLA-A*02:01 with high affinity and could induce CD8+ T-cell responses in vitro. We identified UNC-CDK4-1/HLA-A*02:01 tetramer+ populations in 3 of 6 patients with acute myeloid leukemia who had undergone allogeneic stem cell transplantation. Using tetramer-based, single-cell sorting and T-cell receptor β (TCRβ) sequencing, we identified recurrent UNC-CDK4-1 tetramer–associated TCRβ clonotypes in a patient with a UNC-CDK4-1 tetramer+ population, suggesting in vivo T-cell expansion to UNC-CDK4-1. In parallel, we measured the patients TCRβ repertoire and found it to be highly restricted/oligoclonal. The UNC-CDK4-1 tetramer–associated TCRβ clonotypes represented >17% of the entire TCRβ repertoire—far in excess of the UNC-CDK4-1 tetramer+ frequency—indicating that the recurrent TCRβ clonotypes identified from UNC-CDK-4-1 tetramer+ cells were likely a consequence of the extremely constrained T-cell repertoire in the patient and not in vivo UNC-CDK4-1–driven clonal T-cell expansion. Mapping recurrent TCRβ clonotype sequences onto TCRβ repertoires can help confirm or refute antigen-specific T-cell expansion in vivo. Cancer Immunol Res; 3(3); 228–35. ©2015 AACR.


Dna Sequence | 1998

Nueleotide Sequence of a Three Gene Cluster in Neisseria Gonorrhoeae Encoding Ribosomal Proteins S6, S18, and L9

Patricia A. Ropp; Robert A. Nicholas

A cluster of three genes, rpsF, rpsR, and rpII, encoding the ribosomal proteins S6, S18, and L9, respectively, were cloned and sequenced from Neisseria gonorrhoeae. The order of the genes within the cluster was established as rpsF-rpsR-rpII. Within this cluster an additional open reading frame of unknown identity spanning 108 bp was found between rpsF and rpsR. The putative amino acid sequences deduced from all three genes show a high degree of homology to other bacterial ribosomal proteins.


Antimicrobial Agents and Chemotherapy | 2002

Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae.

Patricia A. Ropp; Mei Hu; Melanie Olesky; Robert A. Nicholas


Pharmaceutical Research | 2008

Microfabricated Particles for Engineered Drug Therapies: Elucidation into the Mechanisms of Cellular Internalization of PRINT Particles

Stephanie E. A. Gratton; Mary E. Napier; Patricia A. Ropp; Shaomin Tian; Joseph M. DeSimone


Analytical Chemistry | 2003

Detection of Attomole Quantitites of DNA Targets on Gold Microelectrodes by Electrocatalytic Nucleobase Oxidation

Mitchell R. Gore; Veronika A. Szalai; Patricia A. Ropp; Ivana V. Yang; and Joel S. Silverman; H. Holden Thorp


Journal of Physical Chemistry B | 2001

Using Density Functional Theory To Design DNA Base Analogues with Low Oxidation Potentials

† Mu-Hyun Baik; Joel S. Silverman; Ivana V. Yang; Patricia A. Ropp; Veronika A. Szalai; and Weitao Yang; H. Holden Thorp

Collaboration


Dive into the Patricia A. Ropp's collaboration.

Top Co-Authors

Avatar

H. Holden Thorp

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Atim A. Enyenihi

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Gary L. Glish

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Gheath Alatrash

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Gregory Lizée

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Paul M. Armistead

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Sally A. Hunsucker

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Tania Rodriguez-Cruz

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Joseph M. DeSimone

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Robert A. Nicholas

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge